IGC Pharma Price Target Raised to $5.50 on Phase 2 CALMA Progress
IGC•Ascendiant Capital Markets raised IGC Pharma’s price target to $5.50, citing recent clinical progress on its IGC-AD1 Alzheimer’s therapy. The firm highlighted potential 2026 data readouts and operational milestones from the Phase 2 CALMA trial as key catalysts for the stock.
1. Price Target Increase
Ascendiant Capital Markets raised its price target for IGC Pharma to $5.50, citing tangible clinical progress on the lead asset IGC-AD1 and forecasting that upcoming data and milestones in 2026 will serve as significant stock catalysts.
2. Phase 2 CALMA Progress
IGC Pharma is advancing IGC-AD1 through the Phase 2 CALMA trial, which evaluates efficacy in managing agitation in Alzheimer’s dementia; the company aims to meet key operational and clinical milestones later this year to support data readouts.
3. Pipeline and AI Applications
Beyond IGC-AD1, the company’s pipeline features TGR-63 targeting amyloid plaques and early-stage programs addressing neurodegeneration, tau proteins and metabolic dysfunctions, with AI-driven drug discovery and trial optimization poised to accelerate development in 2026.
